# HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

> **NCT06631326** · — · COMPLETED · sponsor: **First Hospital of China Medical University** · enrollment: 244 (actual)

## Conditions studied

- HCC - Hepatocellular Carcinoma
- Hepatic Arterial Infusion Chemotherapy
- BCLC Stage C Hepatocellular Carcinoma
- Lenvatinib
- PD-1 Inhibitors

## Interventions

- **PROCEDURE:** hepatic artery infusion chemotherapy
- **DRUG:** Lenvatinib + PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT06631326
- **Lead sponsor:** First Hospital of China Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2025-10-22
- **Final completion:** 2025-10-22
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06631326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06631326, "HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06631326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*